In several non-prostate cancer types, we found that CTNNB1 expression was also significantly higher in TP53 mutated, but not TP53-null or WT breast and pancreatic cancer patient samples, but no correction was observed in bladder and colon cancer samples (Supplementary Fig. S6h). This evidence concerns the gene TP53 and Familial prostate cancer.